Response begins trading on NASDAQ:
This article was originally published in Clinica
Executive Summary
Pharmacogenomic cancer diagnostics specialist Response Genetics commenced trading on the NASDAQ capital market last week (June 5) after issuing an initial public offering of 3 million shares of common stock priced at $7 per share. The Los Angeles, California-based firm intends to use the proceeds for research and development, business expansion and general corporate purposes. On first day of trading, its share price reached a high of $7.49 but closed at $7, the original opening price. The company is registered under the symbol "RGDX".